Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 25, 2005 03:20 ET | Source: Semcon

Semcon -- Ericsson's Design and Development Partner in the Volvo Ocean Race 2005/2006

GOTEBORG, Sweden, April 25, 2005 (PRIMEZONE) -- Semcon will once again take part in developing a yacht for the world's toughest and longest yacht race, this time as the design and development partner...
April 21, 2005 13:20 ET | Source: Munters

Annual General Meeting in Munters AB

STOCKHOLM, Sweden, April 21, 2005 (PRIMEZONE) -- Board of Directors At today's Annual General Meeting in Munters AB, the board members Berthold Lindqvist, Bengt Kjell, Soren Mellstig, Sven...
April 21, 2005 07:05 ET | Source: Munters

Munters Interim Report January -- March 2005

STOCKHOLM, Sweden, April 21, 2005 (PRIMEZONE) -- Munters: - Net sales increased by 8 percent to 1,079 MSEK (996). - Net earnings amounted to 37 MSEK (36). - Earnings per share rose by 2...
April 20, 2005 07:00 ET | Source: Semcon

Semcon Interim Report January -- March 2005

GOTEBORG, Sweden, April 20, 2005 (PRIMEZONE) -- Semcon: STRONG GROWTH AS PROFITS SOAR -- Sales climbed by 14.7% to reach SEK 359 m (313). -- Profit after tax was SEK 14.0 m (7.2). --...
April 20, 2005 01:36 ET | Source: New Wave Group

Interim Report for New Wave Group AB (publ) January-March 2005

STOCKHOLM, Sweden, April 20, 2005 (PRIMEZONE) -- New Wave Group AB: -- During January-Mars sales increased by 10% to SEK 517 (469) m. -- Profit after net financial items decreased by SEK 26.1...
April 13, 2005 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Ordentliche Generalversammlung der Aktionäre der Basilea Pharmaceutica AG

Basel, 13. April 2005 In seiner gestrigen Präsentation an die Aktionäre kommentierte Dr. Anthony Man, CEO der Basilea, das Geschäftsjahr 2004 folgendermassen: "Basilea konzentrierte...
April 13, 2005 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Ordinary General Meeting of Shareholders of Basilea Pharmaceutica AG

Basel, Switzerland, 13th April 2005 In his presentation to shareholders yesterday, Anthony Man, MD, Basilea's CEO, commented on the 2004 business year: "The focus of Basilea over the...
April 13, 2005 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Ordentliche Generalversammlung der Aktionäre der Basilea Pharmaceutica AG

Basel, 13. April 2005 In seiner gestrigen Präsentation an die Aktionäre kommentierte Dr. Anthony Man, CEO der Basilea, das Geschäftsjahr 2004 folgendermassen: "Basilea konzentrierte...
April 08, 2005 03:10 ET | Source: Munters

Munters AB will be Holding a Conference Call Following the Announcement of Munters Interim Report for the First Quarter 2005

STOCKHOLM, Sweden, April 8, 2005 (PRIMEZONE) -- Munters AB: Date: Friday 22 April Time: 2.00 pm CET (1.00 p.m. GMT) Mr Lennart Evrell, CEO and Mr Bernt Ingman, CFO will give an update on the...
April 08, 2005 01:15 ET | Source: Basilea Pharmaceutica AG, Allschwil

Basilea's First-in-Class Antibiotic BAL5788 (Ceftobiprole) Moves into Hospital-Acquired Pneumonia Phase III Clinical Trials. Basilea Delivers on an Additional Important Clinical Milestone

Basel, Switzerland, April 8, 2005 Basilea Pharmaceutica AG announced today the start of its international phase III program for BAL5788, a novel broad spectrum, anti-methicillin resistant...